In addition, a systematic review by J.D.S. Pinho-Jr., which included 30 articles published between 2013 and 2020, confirmed that irisin can act both as a target for prevention and as a biomarker for the presence of obesity-associated comorbidities and cardiometabolic disorders [45]. The gene discussed is FNDC5; the disease is obesity due to melanocortin 4 receptor deficiency.